MX2021001336A - Métodos de terapia génica para controlar la función de órganos. - Google Patents
Métodos de terapia génica para controlar la función de órganos.Info
- Publication number
- MX2021001336A MX2021001336A MX2021001336A MX2021001336A MX2021001336A MX 2021001336 A MX2021001336 A MX 2021001336A MX 2021001336 A MX2021001336 A MX 2021001336A MX 2021001336 A MX2021001336 A MX 2021001336A MX 2021001336 A MX2021001336 A MX 2021001336A
- Authority
- MX
- Mexico
- Prior art keywords
- organ function
- organ
- function
- gene therapy
- therapy methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan métodos y composiciones para controlar la función de los órganos viscerales. Por ejemplo, los métodos y composiciones son útiles para prevenir, inhibir o tratar enfermedades como resultado de controlar, por ejemplo, regular la función de los órganos. En una modalidad, los vectores virales se suministran a un órgano y el virus infecta un nervio que regula una función del órgano. En una modalidad, el vector viral es un vector retrógrado. En una modalidad, el vector viral codifica un producto génico, cuya actividad se controla por un agente o energía que se suministra de manera exógena. El suministro del agente o la energía controla por tanto la función del órgano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862712669P | 2018-07-31 | 2018-07-31 | |
PCT/US2019/044290 WO2020028466A1 (en) | 2018-07-31 | 2019-07-31 | Gene therapy methods to control organ function |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001336A true MX2021001336A (es) | 2021-09-10 |
Family
ID=69230802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001336A MX2021001336A (es) | 2018-07-31 | 2019-07-31 | Métodos de terapia génica para controlar la función de órganos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210301306A1 (es) |
EP (1) | EP3829718A4 (es) |
JP (2) | JP2021533126A (es) |
KR (1) | KR20210052450A (es) |
CN (1) | CN113301956A (es) |
AU (1) | AU2019315445A1 (es) |
BR (1) | BR112021001878A2 (es) |
CA (1) | CA3108324A1 (es) |
EA (1) | EA202190358A1 (es) |
IL (1) | IL280531A (es) |
MX (1) | MX2021001336A (es) |
PH (1) | PH12021550243A1 (es) |
SG (1) | SG11202101042SA (es) |
WO (1) | WO2020028466A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023019565A1 (zh) * | 2021-08-20 | 2023-02-23 | 中国科学院深圳先进技术研究院 | 一种利用交感神经控制血管内皮细胞异质性的方法 |
CN116115758A (zh) * | 2022-11-22 | 2023-05-16 | 上海市内分泌代谢病研究所 | Gabaa受体作为靶点在制备或筛选降血脂、治疗肥胖和/或改善代谢的药物中的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US6342390B1 (en) | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US20050287559A1 (en) | 2004-05-07 | 2005-12-29 | Applera Corporation | Genetic polymorphisms associated with vascular, methods of detection and uses thereof |
WO2006110689A2 (en) * | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
EP3200830B1 (en) * | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
WO2017049252A1 (en) * | 2015-09-17 | 2017-03-23 | Switch Bio, Inc. | Compositions and methods for treating neurological disorders |
CA3011939A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
US20170218842A1 (en) * | 2016-02-02 | 2017-08-03 | General Electric Company | Adjusting Airflow Distortion in Gas Turbine Engine |
WO2017153995A1 (en) * | 2016-03-09 | 2017-09-14 | Assaf Fadi | Using dreadd for neuronal modulation in treating neuronal diseases |
MA44546B1 (fr) * | 2016-06-15 | 2021-03-31 | Univ California | Virus adéno-associés variants et procédés d'utilisation |
WO2018008770A1 (ja) * | 2016-07-06 | 2018-01-11 | 国立研究開発法人国立循環器病研究センター | 末梢神経を操作する方法、脳および脊髄を除く臓器などにおいて神経細胞機能を変化させる機能を発生させる方法、および新規疾病の予防または治療方法、ならびに末梢神経投与用医薬 |
US20210147872A1 (en) * | 2019-10-22 | 2021-05-20 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders |
-
2019
- 2019-07-31 EP EP19845335.9A patent/EP3829718A4/en active Pending
- 2019-07-31 AU AU2019315445A patent/AU2019315445A1/en active Pending
- 2019-07-31 JP JP2021505674A patent/JP2021533126A/ja active Pending
- 2019-07-31 KR KR1020217005554A patent/KR20210052450A/ko active Search and Examination
- 2019-07-31 EA EA202190358A patent/EA202190358A1/ru unknown
- 2019-07-31 US US17/264,752 patent/US20210301306A1/en active Pending
- 2019-07-31 CA CA3108324A patent/CA3108324A1/en active Pending
- 2019-07-31 MX MX2021001336A patent/MX2021001336A/es unknown
- 2019-07-31 CN CN201980065036.9A patent/CN113301956A/zh active Pending
- 2019-07-31 WO PCT/US2019/044290 patent/WO2020028466A1/en active Application Filing
- 2019-07-31 BR BR112021001878-6A patent/BR112021001878A2/pt unknown
- 2019-07-31 SG SG11202101042SA patent/SG11202101042SA/en unknown
-
2021
- 2021-01-31 IL IL280531A patent/IL280531A/en unknown
- 2021-02-01 PH PH12021550243A patent/PH12021550243A1/en unknown
-
2024
- 2024-01-10 JP JP2024001612A patent/JP2024041871A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210301306A1 (en) | 2021-09-30 |
JP2024041871A (ja) | 2024-03-27 |
CA3108324A1 (en) | 2020-02-06 |
WO2020028466A1 (en) | 2020-02-06 |
CN113301956A (zh) | 2021-08-24 |
IL280531A (en) | 2021-03-25 |
EA202190358A1 (ru) | 2021-05-04 |
KR20210052450A (ko) | 2021-05-10 |
AU2019315445A1 (en) | 2021-03-18 |
PH12021550243A1 (en) | 2021-11-22 |
SG11202101042SA (en) | 2021-02-25 |
EP3829718A4 (en) | 2022-06-22 |
BR112021001878A2 (pt) | 2021-04-27 |
JP2021533126A (ja) | 2021-12-02 |
EP3829718A1 (en) | 2021-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550243A1 (en) | Gene therapy methods to control organ function | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
MX2020000294A (es) | Metodos y sistemas para regular condicionalmente la expresion genica. | |
PE20181330A1 (es) | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer | |
MX2018005286A (es) | Constructo genetico. | |
EP4345165A3 (en) | Gene therapy for retinitis pigmentosa | |
MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
MX2023008760A (es) | Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a. | |
JP2016512781A5 (es) | ||
MX2018005588A (es) | Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. | |
MX2018005886A (es) | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. | |
AU2018339164A1 (en) | Artificial genome manipulation for gene expression regulation | |
EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
CO2022012917A2 (es) | Vectores de genoterapia para tratar enfermedades cardíacas | |
MX2019008105A (es) | Virus. | |
MX2020013313A (es) | Terapia genica cardiaca con aav para cardiomiopatia. | |
MX2018011975A (es) | Terapia de combinacion para tratamiento de leucemia mieloide aguda. | |
MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
MX2023003984A (es) | Metodos y composiciones para terapia genica con placofilina-2. | |
PH12018501695A1 (en) | Substituted -oxyimidazolyl-carboxamides as pest control agents | |
MX2023004328A (es) | Formulaciones y metodos para controlar las larvas del gusano de raiz. | |
WO2018195360A8 (en) | Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia | |
WO2019018451A3 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY |